CN109652334A - A kind of complex microbial inoculum and its preparation method and application - Google Patents
A kind of complex microbial inoculum and its preparation method and application Download PDFInfo
- Publication number
- CN109652334A CN109652334A CN201910030845.8A CN201910030845A CN109652334A CN 109652334 A CN109652334 A CN 109652334A CN 201910030845 A CN201910030845 A CN 201910030845A CN 109652334 A CN109652334 A CN 109652334A
- Authority
- CN
- China
- Prior art keywords
- bacterium
- freeze
- microbial inoculum
- bifidobacterium longum
- complex microbial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002068 microbial inoculum Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims description 34
- 241000894006 Bacteria Species 0.000 claims abstract description 143
- 239000000843 powder Substances 0.000 claims abstract description 68
- 241001608472 Bifidobacterium longum Species 0.000 claims abstract description 62
- 229940009291 bifidobacterium longum Drugs 0.000 claims abstract description 62
- 241000194032 Enterococcus faecalis Species 0.000 claims abstract description 61
- 240000001929 Lactobacillus brevis Species 0.000 claims abstract description 56
- 235000013957 Lactobacillus brevis Nutrition 0.000 claims abstract description 56
- 241000235072 Saccharomyces bayanus Species 0.000 claims abstract description 52
- 241000193830 Bacillus <bacterium> Species 0.000 claims abstract description 11
- 230000036541 health Effects 0.000 claims abstract description 8
- 230000036039 immunity Effects 0.000 claims abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 claims abstract description 5
- 238000000855 fermentation Methods 0.000 claims description 50
- 230000004151 fermentation Effects 0.000 claims description 50
- 239000007788 liquid Substances 0.000 claims description 42
- 239000003223 protective agent Substances 0.000 claims description 25
- 229930006000 Sucrose Natural products 0.000 claims description 22
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 22
- 239000005720 sucrose Substances 0.000 claims description 22
- 108010010803 Gelatin Proteins 0.000 claims description 20
- 239000008273 gelatin Substances 0.000 claims description 20
- 229920000159 gelatin Polymers 0.000 claims description 20
- 235000019322 gelatine Nutrition 0.000 claims description 20
- 235000011852 gelatine desserts Nutrition 0.000 claims description 20
- 238000004321 preservation Methods 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 7
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 6
- 239000008107 starch Substances 0.000 claims description 6
- 235000019698 starch Nutrition 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 4
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 claims description 4
- 235000013923 monosodium glutamate Nutrition 0.000 claims description 4
- 229940073490 sodium glutamate Drugs 0.000 claims description 4
- 239000006071 cream Substances 0.000 claims description 3
- 238000004821 distillation Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 241001478240 Coccus Species 0.000 claims description 2
- 230000001142 anti-diarrhea Effects 0.000 claims description 2
- 235000013336 milk Nutrition 0.000 claims description 2
- 239000008267 milk Substances 0.000 claims description 2
- 210000004080 milk Anatomy 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims 1
- 238000005238 degreasing Methods 0.000 claims 1
- 235000015110 jellies Nutrition 0.000 claims 1
- 239000008274 jelly Substances 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 abstract description 25
- 230000004083 survival effect Effects 0.000 abstract description 17
- 230000001717 pathogenic effect Effects 0.000 abstract description 15
- 244000052769 pathogen Species 0.000 abstract description 9
- 230000008485 antagonism Effects 0.000 abstract description 5
- 230000013370 mutualism Effects 0.000 abstract description 3
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 42
- 238000000034 method Methods 0.000 description 21
- 235000020183 skimmed milk Nutrition 0.000 description 20
- 241000282472 Canis lupus familiaris Species 0.000 description 19
- 239000002609 medium Substances 0.000 description 19
- 244000005700 microbiome Species 0.000 description 18
- 239000012530 fluid Substances 0.000 description 16
- 239000001963 growth medium Substances 0.000 description 16
- 238000002474 experimental method Methods 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 14
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical group C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 14
- 239000002054 inoculum Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 13
- 230000000968 intestinal effect Effects 0.000 description 12
- 238000004519 manufacturing process Methods 0.000 description 12
- 239000004615 ingredient Substances 0.000 description 11
- 230000004888 barrier function Effects 0.000 description 10
- 239000001888 Peptone Substances 0.000 description 9
- 108010080698 Peptones Proteins 0.000 description 9
- 229940099352 cholate Drugs 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 235000019319 peptone Nutrition 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 241000607142 Salmonella Species 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 230000001954 sterilising effect Effects 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 229920001817 Agar Polymers 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 239000008272 agar Substances 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 230000003115 biocidal effect Effects 0.000 description 6
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000002253 acid Substances 0.000 description 5
- 244000052616 bacterial pathogen Species 0.000 description 5
- 210000000981 epithelium Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 239000006041 probiotic Substances 0.000 description 5
- 235000018291 probiotics Nutrition 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 4
- 241000304886 Bacilli Species 0.000 description 4
- 239000004380 Cholic acid Substances 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 229940041514 candida albicans extract Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000019416 cholic acid Nutrition 0.000 description 4
- 229960002471 cholic acid Drugs 0.000 description 4
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 244000000010 microbial pathogen Species 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000006152 selective media Substances 0.000 description 4
- 235000015170 shellfish Nutrition 0.000 description 4
- 210000000813 small intestine Anatomy 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 239000012138 yeast extract Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 241000186000 Bifidobacterium Species 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 3
- 241000235342 Saccharomycetes Species 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- 230000013872 defecation Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 210000000822 natural killer cell Anatomy 0.000 description 3
- 210000004493 neutrocyte Anatomy 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 238000009631 Broth culture Methods 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- 239000003390 Chinese drug Substances 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 2
- 125000000415 L-cysteinyl group Chemical class O=C([*])[C@@](N([H])[H])([H])C([H])([H])S[H] 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 102000016943 Muramidase Human genes 0.000 description 2
- 108010014251 Muramidase Proteins 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011148 calcium chloride Nutrition 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 235000020247 cow milk Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000020256 human milk Nutrition 0.000 description 2
- 210000004251 human milk Anatomy 0.000 description 2
- 230000015784 hyperosmotic salinity response Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- -1 iron ion Chemical class 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 238000009630 liquid culture Methods 0.000 description 2
- 210000001699 lower leg Anatomy 0.000 description 2
- 229960000274 lysozyme Drugs 0.000 description 2
- 235000010335 lysozyme Nutrition 0.000 description 2
- 239000004325 lysozyme Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000009781 safety test method Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 235000021391 short chain fatty acids Nutrition 0.000 description 2
- 150000004666 short chain fatty acids Chemical class 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 238000007711 solidification Methods 0.000 description 2
- 230000008023 solidification Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000004347 surface barrier Methods 0.000 description 2
- 231100000041 toxicology testing Toxicity 0.000 description 2
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- PLXMOAALOJOTIY-FPTXNFDTSA-N Aesculin Natural products OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1Oc2cc3C=CC(=O)Oc3cc2O PLXMOAALOJOTIY-FPTXNFDTSA-N 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- QWIZNVHXZXRPDR-UHFFFAOYSA-N D-melezitose Natural products O1C(CO)C(O)C(O)C(O)C1OC1C(O)C(CO)OC1(CO)OC1OC(CO)C(O)C(O)C1O QWIZNVHXZXRPDR-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 241000588921 Enterobacteriaceae Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102100032241 Lactotransferrin Human genes 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 108010084754 Tuftsin Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106164 cephalexin Drugs 0.000 description 1
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000000151 deposition Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- AIUDWMLXCFRVDR-UHFFFAOYSA-N dimethyl 2-(3-ethyl-3-methylpentyl)propanedioate Chemical class CCC(C)(CC)CCC(C(=O)OC)C(=O)OC AIUDWMLXCFRVDR-UHFFFAOYSA-N 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- XHCADAYNFIFUHF-TVKJYDDYSA-N esculin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC2=C1OC(=O)C=C2 XHCADAYNFIFUHF-TVKJYDDYSA-N 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000002175 goblet cell Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 102000050459 human LTF Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QWIZNVHXZXRPDR-WSCXOGSTSA-N melezitose Chemical compound O([C@@]1(O[C@@H]([C@H]([C@@H]1O[C@@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O)CO)CO)[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O QWIZNVHXZXRPDR-WSCXOGSTSA-N 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229940066779 peptones Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002633 protecting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000001533 respiratory mucosa Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940035670 tuftsin Drugs 0.000 description 1
- IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
- A23C9/127—Fermented milk preparations; Treatment using microorganisms or enzymes using microorganisms of the genus lactobacteriaceae and other microorganisms or enzymes, e.g. kefir, koumiss
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/121—Brevis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/533—Longum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/24—Lactobacillus brevis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Nutrition Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of complex microbial inoculum, including Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and streptococcus fecalis.Complex microbial inoculum of the present invention, survival rate is high after inhibiting pathogen ability strong and being made as freeze-dried powder.Without mutual antagonism between four kinds of bacterial strains of complex microbial inoculum of the present invention, it can be with mutualism, and the bifidobacterium longum, the Bacillus acidi lactici, the streptococcus fecalis have powerful antagonism to pathogen, and then the complex microbial inoculum for forming four kinds of bacterial strains has the function of good recuperating gastrointestinal tract health, improves immunity.
Description
Technical field
The invention belongs to human body microecology technical field more particularly to a kind of complex microbial inoculum and its preparation sides
Method and application.
Background technique
Various microorganisms (bacterium) are often attached to human body from different environment, and can settle down and not medium well at certain position
Length raises up seed, this to phenomenon be commonly referred to as " bacteria planting ".The microorganism of field planting must be continuing to supply nutrition by human body
Substance could grow and breed, and could and then have an impact to human body.
Typically, human body has following several immunologic mechanisms:
A. structural barriers: " structural barriers " that child resists external cause pathogeny imcrobe infection include body surface barrier and inside
Barrier.Body surface barrier is made of the mucous membrane that lining in the cavity for being covered on the skin of body surface and communicating with the outside world, and is body defenses
The first line of defence of microorganism.As mucous membrane of small intestine epithelium not only has the function of digesting and assimilating nutriment while and one
The important barrier (Kato etc.) of harmful substance (including bacterium, virus, pathogen, allergen macromolecular substances etc.) is resisted, especially
It is blood-brain barrier, it can prevent pathogenic microorganism in blood and other macromolecular substances from entering brain tissue and the ventricles of the brain.In addition,
The movement of gastral wriggling and respiratory mucosa cilium not only has mechanical scavenging effect, mucous epithelium to microorganism in enteric cavity
Periodically fall off replacement reduce the chance that various microorganisms build group.
B. chemical barrier: respiratory tract and the various secretion of each organ secretion of alimentary canal (contain lysozyme, complement, naturally
Antibody etc.) to constitute child anti-infectious " chemical barrier ".As the saliva (mainly containing lysozyme) in child oral cavity can kill
Multiple pathogenic microorganisms, the gastric acid and pepsin of stomachial secretion can destroy daily ration antigen and can effectively inhibit multiple-microorganism from
Oropharynx enters small intestine, and the certain micro-organisms for entering small intestine is also very sensitive to the bile in small intestine;In addition, the egg in pancreatic juice
White enzyme can destroy bacterial cell membrane.The mucus of enteron aisle goblet cell secretion can both protect fragile enteric epithelium from mechanical damage,
Cultivation antigenic substance is wrapped but also as a kind of adhesive matrix, it is made to be easier to be degraded by the enzyme of pancreas and epithelial cells
(Gaskins, 1999);In addition, mucous membrane can protect the destruction and prevention cause of disease for the digestive ferment that epithelium is secreted from intestinal flora
Body invades epithelium (Nevtre etc., 1987)
C. biological barrier: a large amount of normal floras in enteron aisle are otherwise known as " biological barrier ".Hentges etc. (1983) recognizes
Main function for normal flora is that invading micro-organism is prevented to build group in enteron aisle.Gaskin etc. (1996) report thinks normal
Flora can stimulate the development of animal mechanism to enhance immunity of organism.The various antibacterial materials such as bacteriocin of normal flora secretion
It can inhibit certain anaerobic bacteria breedings.In addition, normal flora and pathogenic microorganism are building group point, exist on the life conditions such as nutrition
Competitive relation, also inhibit pathogenic microorganism growth and development and breeding.
D. the antibacterial material in phagocyte, natural killer cells and body fluid: the phagocyte (part in child's blood
From breast milk) it include neutrophil leucocyte and Monocytes/Macrophages.Neutrophil leucocyte has weight in body defenses bacterium infection
It acts on.Sterilization in neutrophil leucocyte/infiltration enhancing albumen (BPl) not only to gram-positive bacteria have wide spectrum inhibit and
Lethal effect, and have and neutralize bacterial endotoxin, the effects of inhibiting cytokine release and resist endotoxin lethal effect
(Ke Yan etc., 1998).Natural killer cells (NK cell) can produce interferon, plays cytotoxicity and kills infection cell.
In addition, the complement, Tuftsin in body fluid all play important nospecific immunity effect.
E. newborn source non-antibody protected protein: human lactoferrin (Loctoferrin, LTF) is that a kind of non-antibody is protected in breast milk
Albumen is protected, is that newborn child transports iron ion and as mother's mammary gland and a kind of defensive barrier of ewborn infant enteron aisle, in addition,
Also have and adjust nospecific immunity, promotes the functions such as granulocyte and lymphocyte mitosis.
Probiotics is a kind of strain beneficial to human body, has effects that adjust intestinal health, but existing probiotics is general
All over having the drawback that 1, inhibit pathogen ability weaker.2, the lyophilized technique of freeze-dried vaccine powder is directly related to bacterium powder after freeze-drying
Survival rate, after being made as freeze-dried vaccine powder, number of viable is lower, influences its effectiveness.
Summary of the invention
For this purpose, to be to provide a kind of inhibition pathogen ability strong and be made as first technical problem to be solved by this invention
The high complex microbial inoculum of survival rate after freeze-dried powder.Second technical problem to be solved by this invention is in the prior art
The low problem of the obtained Viable detection of complex microbial inoculum of freeze-dried vaccine powder technique, and then provide a kind of viable bacteria survival
The preparation method of the high long complex microbial inoculum of rate.
Complex microbial inoculum of the invention, including Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and streptococcus fecalis.Institute
Lactobacillus brevis is stated in submission on July 17th, 2018 China Committee for Culture Collection of Microorganisms's common micro-organisms center
(CGMCC) give preservation, deposit number is CGMCC NO. 16125, and Latin is named as Lactobacillus brevis;
The bifidobacterium longum is in submission on July 17th, 2018 China Committee for Culture Collection of Microorganisms's common micro-organisms center
(CGMCC) give preservation, deposit number is CGMCC NO.16126, and Latin is named as Bifldobacterium
longum;The saccharomyces bayanus bacterium is in submission on July 17th, 2018 China Committee for Culture Collection of Microorganisms common micro-organisms
Center (CGMCC) gives preservation, and deposit number is CGMCC NO. 16127, and Latin is named as Saccharomyces
bayanus;The streptococcus fecalis is in the commonly micro- life of submission on July 17th, 2018 China Committee for Culture Collection of Microorganisms
Object center (CGMCC) gives preservation, and deposit number is CGMCC NO.16128, and Latin is named as streptococcus
faecalis.The address China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC), i.e. preservation address are
Yard 1, BeiChen xi Road, Chaoyang District, Beijing City 3.
The 16SrDNA sequence of the Lactobacillus brevis has the sequential structure as shown in SEQ ID NO.1, the SEQ ID
The sequential structure of NO.1 is specific as follows:
ggatgaacgctggcggcgtgcctaatacatgcaagtcgaacgagttctcgttgatgatcggtgcttgc
ac cgagattcaacatggaacgagtggcggacgggtgagtaacacgtgggtaacctgcccttaagtgggggataac
atttggaaacagatgctaataccgcatagatccaagaaccgcatggttcttggctgaaagatggcgtaagctatc
gcttttggatggacccgcggcgtattagctagttggtgaggtaatggctcaccaaggcgatgatacgtagccgaa
ctgagaggttgatcggccacattgggactgagacacggcccaaactcctacgggaggcagcagtagggaatctt c
cacaatggacgcaagtctgatggagcaacgccgcgtgagtgaagaaggctttcgggtcgtaaaactctgatgtt g
gagaagaatggtcggcagagtaactgttgccggcgtgacggtatccaaccagaaagccacggctaactacgtg cc
agcagccgcggtaatacgtaggtggcaagcgttatccagatttattgggcgtaaagcgagcgcaggcggtttt tt
aagtctgatgtgaaagccctcggcttaaccgaggaagcgcatcggaaactgggaaacttgagtgcagaagag gac
agtggaactccatgtgtagcggtgaaatgcgtagatatatggaagaacaccagtggcgaaggcggctgtct ggtc
tgtaactgacgctgaggctcgaaagcatgggtagcgaacaggattagataccctggtagtccatgccgtaa acga
tgaatgctaggtgttggagggtttccgcccttcagtgccgcagctaacgcattaagcattccgcctggggag tac
gaccgcaaggttgaaactcaaaggaattgacgggggcacgcacaagcggtggagcatgtggtttaattcga agca
acgcgaagaaccttaccaggtcttgacatcttttgatcacttgagagatcaggtttccccttcgggggcaaa atg
acaggtggtgcatggttgtcgtcagctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaaccctt at
gactagttgccagcatttagttgggcactctagtaagactgccggtgacaaaccggaggaaggtggggatga cgt
caaatcatcatgccccttatgacctgggctacacacgtgctacaatggatggtacaacgagttgcgagaccg cga
ggtcaagctaatctcttaaagccattctcagttcggactgtaggctgcaactcgcctacacgaagtcggaatc gc
tagtaatcgcggatcagcacgccgcggtgaatacgttcccgggccttgtacacaccgcccgtcacaccatgag ag
tttgtaacacccgaagccggtggcgtaacccttttagggagcgagccgtct。
The 16SrDNA sequence of the bifidobacterium longum has the sequential structure as shown in SEQ ID NO.2;The SEQ
The sequential structure of ID NO.2 is specific as follows:
caggatgaacgctggcggcgtgcttaacacatgcaagtcgaacgggatccctggcagcttgctgtcggg
gtgagagtggcgaacgggtgagtaatgcgtgaccaacctgccctgtgcaccggaatagctcctggaaacgggtg g
taataccggatgctccgctccatcgcatggtggggtgggaaatgcttttgcggcatgggatggggtcgcgtccta
tcagcttgttggcggggtgatggcccaccaaggcgttgacgggtagccggcctgagagggtgaccggccacatt g
ggactgagatacggcccagactcctacgggaggcagcagtggggaatattgcacaatgggcgcaagcctgat gca
gcgacgccgcgtgcgggatggaggccttcgggttgtaaaccgcttttgttcaagggcaaggcacggtttcgg ccg
tgttgagtggattgttcgaataagcaccggctaactacgtgccagcagccgcggtaatacgtagggtgcgag cgt
tatccggatttattgggcgtaaagggctcgtaggcggttcgtcgcgtccggtgtgaaagtccatcgcctaacg gt
ggatctgcgccgggtacgggcgggctggagtgcggtaggggagactggaattcccggtgtaacggtggaatg tgt
agatatcgggaagaacaccaatggcgaaggcaggtctctgggccgtcactgacgctgaggagcgaaagcg tgggg
agcgaacaggattagataccctggtagtccacgccgtaaacggtggatgctggatgtggggccctttcca cgggt
cccgtgtcggagccaacgcgttaagcatcccgcctggggagtacggccgcaaggctaaaactcaaaga aattgac
gggggcccgcacaagcggcggagcatgcggattaattcgatgcaacgcgaagaaccttacctgggct tgacatgt
gccggatcgccgtggagacacggtttcccttcggggccggttcacaggtggtgcatggtcgtcgtcag ctcgtgt
cgtgagatgttgggttaagtcccgcaacgagcgcaaccctcgccgcatgttgccagcgggtgatgccg ggaactc
atgtgggaccgccggggtcaactcggaggaaggtggggatgacgtcagatcatcatgccccttacgt ccagggct
tcacgcatgctacaatggccggtacaacgcggtgcgacacggtgacgtggggcggatcgctgaaa accggtctca
gttcggatcgcagtctgcaactcgactgcgtgaaggcggagtcgctagtaatcgcggatcagcaa cgccgcggtg
aatgcgttcccgggccttgtacacgccgcccgtcaagtcatgaaagtgggtagcacccgaagcc ggtggcccgac
ccttgtggggggagccgtctaaggtgaga。
The 26S rDNA sequence of the saccharomyces bayanus bacterium has the sequential structure as shown in SEQ ID NO.3;The SEQ ID
The sequential structure of NO.3 is specific as follows:
atgcttagtacggcgagtgagcggcaaaagctcaaatttgaaatctggtaccttcggtgcccgagttg
ta atttggagagggcaactttggggccgttccttgtctatgttccttggaacaggacgtcatagagggtgagaat
ccc gtgtggcgaggagtgcggttctttgtaaagtgccttcgaagagtcgagttgtttgggaatgcagctctaagt
gggt ggtaaattccatctaaagctaaatattggcgagagaccgatagcgaacaagtacagtgatggaaagatgaa
aa gaactttgaaaagagagtgaaaaagtacgtgaaattgttgaaagggaagggcatttgatcagacatggtgttt
tg tgccctctgctccttgtgggtaggggaatctcgcatttcactgggccagcatcagttttggtggcaggataaa
tcca taggaatgtagcttgcctcggtaagtattatagcctgtgggaatactgccagctgggactgaggactgcga
cgta agtcaaggatgctggcataatggttatatgccgcccgtcttgaaacacg。
The 16SrDNA sequence of the streptococcus fecalis has the sequential structure as shown in SEQ ID NO.4.The SEQ ID
The sequential structure of NO.4 is specific as follows:
gaacgctggcggcgtgcctaatacatgcaagtagaacgctgaagagaggagcttgctcttcttggatga
gttgcgaacgggtgagtaacgcgtaggtaacctgccttgtagcgggggataactattggaaacgatagctaatac
cgcataacaatggatgacacatgtcatttatttgaaaggggcaattgctccactacaagatggacctgcgttgtat
tagctagtaggtgaggtaatggctcacctaggcgacgatacatagccgacctgagagggtgatcggccacactg g
gactgagacacggcccagactcctacgggaggcagcagtagggaatcttcggcaatgggggcaaccctgacc gag
caacgccgcgtgagtgaagaaggttttcggatcgtaaagctctgttgtaagtcaagaacgggtgtgagagtg gaa
agttcacactgtgacggtagcttaccagaaagggacggctaactacgtgccagcagccgcggtaatacgta ggtc
ccgagcgttgtccggatttattgggcgtaaagcgagcgcaggcggtttgataagtctgaagttaaaggctgt ggc
tcaaccatagttcgctttggaaactgtcaaacttgagtgcagaaggggagagtggaattccatgtgtagcgg tga
aatgcgtagatatatggaggaacaccggtggcgaaagcggctctctggtctgtaactgacgctgaggctcga aag
cgtggggagcgaacaggattagataccctggtagtccacgccgtaaacgatgagtgctaggtgttggatcct ttc
cgggattcagtgccgcagctaacgcattaagcactccgcctggggagtacgaccgcaaggttgaaactcaaa gga
attgacgggggcccgcacaagcggtggagcatgtggtttaattcgaagcaacgcgaagaaccttaccaggt cttg
acatcccgatgctatttctagagatagaaagttacttcggtacatcggtgacaggtggtgcatggttgtcgtc ag
ctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaacccctattgttagttgccatcattcagttggg
cactctagcgagactgccggtaataaaccggaggaaggtggggatgacgtcaaatcatcatgccccttatgacct
gggctacacacgtgctacaatggttggtacaacgagttgcgagtcggtgacggcgagctaatctcttaaagccaa
tctcagttcggattgtaggctgcaactcgcctacatgaagtcggaatcgctagtaatcgcggatcagcacgccgcg
gtgaatacgttcccgggccttgtacacaccgcccgtcacaccacgagagtttgtaacacccgaagt。
The complex microbial inoculum is preparing recuperating gastrointestinal tract health and/or is improving the health care product of immunity, cream system
Application in product, drug.
Preferably, the complex microbial inoculum is in the health care product of preparation treatment and/or pre- anti-diarrhea, drug
Using.
The preparation method of complex microbial inoculum of the invention includes the following steps: to take the Lactobacillus brevis, long pair
Discrimination bacillus, saccharomyces bayanus bacterium and streptococcus fecalis are made as freeze-dried powder respectively, remix uniformly to obtain the final product.
Preferably, the preparation method of the complex microbial inoculum specifically comprises the following steps: respectively to the short cream
Protective agent is added in bacillus, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis, is uniformly mixed, is set
The pre-freeze 1-3h at a temperature of -30~-50 DEG C, distil 10-20h at a temperature of being subsequently placed in -10~-20 DEG C, then is placed in -10
Distil 10-20h at a temperature of~-25 DEG C, then in 20-30 DEG C of at a temperature of secondary distillation 1-5h, places 1-5h under vacuum
Afterwards to get the freeze-dried powder of the Lactobacillus brevis, the freeze-dried powder of the bifidobacterium longum, the freeze-dried powder of the saccharomyces bayanus bacterium and institute
The freeze-dried powder for stating streptococcus fecalis, by four kinds of freeze-dried powders be uniformly mixed to get.
Preferably, the protective agent be skimmed milk power, maltose, sucrose, soluble starch, mannitol, sodium glutamate,
One of L-cysteine, gelatin are a variety of.
Preferably, the preparation method of the complex microbial inoculum, specifically comprises the following steps:
(1) Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis are taken, is fermented respectively
Culture, obtains the fermentation liquid of the Lactobacillus brevis, the fermentation liquid of the bifidobacterium longum, the fermentation liquid of the saccharomyces bayanus bacterium, institute
State the fermentation liquid of streptococcus fecalis;
(2) four kinds of fermentation liquids that fermentation obtains in step (1) are taken, placing it in revolving speed respectively is 8000-12000 r/min
Under, it is centrifuged 10-30min, bacterium mud is collected, obtains four kinds of bacterium muds;
(3) protective agent, the protective agent and the bacterium mud are separately added into bacterium mud obtained in step (2)
Weight ratio is 3:1, is uniformly mixed, pre-freeze 3h at a temperature of placing it in -40 DEG C distils at a temperature of being subsequently placed in -15 DEG C
15h, then the 2h that distils at a temperature of being placed in 25 DEG C make the water content of the bacterium mud less than 5%, obtain after placing 2h under vacuum
The freeze-dried powder of the Lactobacillus brevis, the freeze-dried powder of the bifidobacterium longum, the saccharomyces bayanus bacterium freeze-dried powder and the excrement hammer
The freeze-dried powder of bacterium, by four kinds of freeze-dried powders be uniformly mixed to get.
It is further preferred that in step (1), the Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and institute
Streptococcus fecalis is stated, obtains fermentation liquid by three grade fermemtation.
Above-mentioned technical proposal of the invention, has the advantage that compared with prior art
(1) complex microbial inoculum of the present invention separates a large amount of Lactobacillus brevis, long bifid bar from infant faeces
Bacterium, saccharomyces bayanus bacterium and streptococcus fecalis, according to the test such as pathogeny bacterium ability, acid producing ability, digestion power is inhibited, filtering out can
The preferably bacterial strain of digestible protein, meat slag, corn, starch, leaf, grass, obtains complex microbial inoculum of the present invention,
It is used for human body, because homologous strain colonizes well, Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and streptococcus fecalis can inhibit
Harmful bacteria, and then safeguard the intestinal flora ecological balance, biological barrier is formed, invasion of the harmful bacteria to enteron aisle is inhibited.In addition, institute
Stating complex microbial inoculum can also promote intestines peristalsis and thallus raised growth to change by generating a large amount of short chain fatty acids
Osmotic pressure and prevent constipation.In addition, in thallus disintegration product and metabolin containing there are many enzyme, small peptide, short chain fatty acids etc. at
Point, the advantages such as supplement the nutrients.
(2) complex microbial inoculum of the present invention, in the enterogastric diseases of people, especially diarrhea has been played very
Good preventive and therapeutic action, and the deficiency of antibiotic and vaccine is compensated for through a variety of ways, for the healthy of the mankind and obtain
It obtains safe food and opens new approach.
(3) complex microbial inoculum of the present invention, the suppression to Escherichia coli, salmonella, staphylococcus aureus
Bacterium is relatively large in diameter, and has stronger inhibition pathogen ability.
(4) complex microbial inoculum of the present invention, acid and bile salt tolerance is good, and by the techniques such as freeze-dried powder behaviour
Strain activity is still ideal after work, long shelf-life of seed.And the system of the complex microbial inoculum through the invention
Preparation Method preparation, in preparation process, using specific protective agent, the holding for making to be made as each microorganism after freeze-dried powder higher is deposited
Motility rate.
Detailed description of the invention
Fig. 1 is the bacterium solution microscopic examination result figure of Lactobacillus brevis of the present invention;
Fig. 2 is the bacterium solution microscopic examination result figure of bifidobacterium longum of the present invention;
Fig. 3 is the bacterium solution microscopic examination result figure of saccharomyces bayanus bacterium of the present invention;
Fig. 4 is the bacterium solution microscopic examination result figure of streptococcus fecalis of the present invention.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation description, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts it is all its
His embodiment, shall fall within the protection scope of the present invention.
The separation screening of 1 bacterial strain of embodiment
The complex microbial inoculum of the present embodiment, including Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and streptococcus fecalis.
The Lactobacillus brevis is in submission on July 17th, 2018 China Committee for Culture Collection of Microorganisms's common micro-organisms center
(CGMCC) give preservation, deposit number is CGMCC NO. 16125;The bifidobacterium longum was submitted on July 17th, 2018
China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC) gives preservation, deposit number CGMCC
NO. 16126;The saccharomyces bayanus bacterium is commonly micro- in submission on July 17th, 2018 China Committee for Culture Collection of Microorganisms
Bio-Centers (CGMCC) give preservation, and deposit number is CGMCC NO.16127;The streptococcus fecalis was July 17 in 2018
Day submits China Committee for Culture Collection of Microorganisms's common micro-organisms center (CGMCC) to give preservation, and deposit number is
CGMCC NO.16128。
The excrement of Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and streptococcus fecalis of the present invention from newborn and infant
Just separation in, and by the assay optimizations such as bacteriostatic test, digestion power test, acid and alkali resistance sieve from 84 kinds of beneficial bacteriums therein
Wherein four outstanding strains are selected after choosing.It is isolated by the following method:
By 1 gram of human body intestinal canal excrement, loading is put in the sterilizing bottle by 30 glass marbles plus physiological saline makees 100 times of dilutions
After sufficiently beating, 10 are remake-3、10-4, successively to 10-8Dilution takes 10-4、10-5、 10-6、10-7、10-8Five dilutions
Bacterium solution is inoculated in the general agar plate of LYT, Yihong, methylene blue agar, BB (BS) Bifidobacterium selective medium, LBS respectively
(LC) Bacillus acidi lactici selective medium, EC enterococcus select base and Sb saccharomycete selects base.Every kind of culture medium connects 6 plates, inoculation
Spinning upside down culture dish immediately afterwards spreads inoculation liquid uniformly in dish surface.Wherein make aerobic culture for 3, after 24 hours i.e.
Observation.Another 3 are made Anaerobic culturel 48 hours.By visually observing and 45 DEG C of angle refraction light observations of disecting microscope.By every kind
Bacterium colony is transplanted to one bacterium colony of one bacterium colony of LYT agar and fluid nutrient medium again, does anaerobism and aerobic respectively, while smear is made
Gram stain microscopy isolates 138 bacterial strains, carries out qualification result and belongs to 8 sections, 36 kinds of bacterium of 11 categories, wherein dividing
From the strain filtered out, monthly subculture is primary, was lyophilized and saves before 5 generations.
Wherein, the specific method is as follows for the separation and breeding of the saccharomyces bayanus bacterium:
1g sample is taken, is added in 100ml PTYG culture medium, is cultivated in constant-temperature table, 30 DEG C of cultivation temperature, revolving speed
180r/min, incubation time are for 24 hours.
By the sample after enrichment, 1ml is taken to carry out 10 times of gradient dilutions, takes 3 suitable dilutions on improvement SB plate
It is coated, 30 DEG C of culture 36h, picking colonies typical is further purified 2~3 times with improvement SB plate streaking.
Wherein, saccharomycete then has no selection characteristic, therefore has no way of preparing selective medium.Because it is to the resistance to of vancomycin
By characteristic, and its distinctive colonial morphology is combined, after being cultivated under aerobic conditions, can be distinguished with other bacterium colonies.Therefore,
The improvement SB culture medium used includes the following raw material: peptone (Oxoid) 1%, maltose 4%, 10% tartaric acid
1.4%, powdered beef 0.35%, sodium chloride 0.5%, vancomycin 10ug/ml, agar 2%;Its condition of culture is as follows: pH value is
5.8-6.0, temperature are 30 DEG C, cultivate 36h.
The specific method is as follows for the separation and breeding of the streptococcus fecalis:
Excrement 1g is taken, is placed in the triangular flask equipped with 10ml buffered peptone water, shaken well.By 10 times of gradient dilutions,
Select each 0.1ml coating KF agar plate of 3 acceptable diluent degree, 37 DEG C of culture 48h.Select white, surface smooth bumps, edge
Neatly, the feature bacterium colony of diameter about 1.0~1.5mm.It passes and carries out Gram's staining after PTYG inclined-plane culture, selecting microscopy is
Gram-positive, circle form oval, and the bacterial strain of single, pairs of or short catenation purifies culture.By bacterial strain after purification into
Row growth characteristics are tested, 6.5% sodium chloride broth culture medium of inoculation and aesculin inclined-plane, after 37 DEG C of culture 48h, select seven leaves
The bacterial strain grown in the glycosides hydrolysis positive, 6.5% sodium chloride broth culture medium is as bacterial strain to be sieved.
Strain to be tested is inoculated with PTYG fluid nutrient medium, 37 DEG C of culture 48h, switching plate, picking single colonie connects respectively
Kind on the basis PTYG semisolid culturemedium and PTYG solid slope, 38 DEG C of 48 h of culture, and by screen obtain it is acidproof and resistance to
Cholate function admirable, and bacterial strain that is well-grown, meeting safety testing.
Wherein, the isolation medium of the streptococcus fecalis is buffered peptone water solution, specifically includes following ingredient: egg
White peptone 10g, Na2HPO42g, glucose 5g, K2HPO42g, KCl 5g, distilled water 1000ml.The preparation method is as follows: taking 10ml
Buffered peptone water is placed in 50ml triangular flask, is added a small amount of bead, spare after 121 DEG C of sterilizing 15min.Due to streptococcus fecalis
There is tolerance to Sodium azide, while there is the characteristic for being resistant to 45 DEG C of high temperature, the streptococcus fecalis selective medium selects city
The KF culture medium sold carries out enterococcal separation in conjunction with high temperature culture conditions.By verifying, this method can be efficiently separated
Streptococcus fecalis out.
The screening of seed bacterial strain is carried out according to following standard: (1) without interior exotoxin, it is nontoxic, harmless, safe, without secondary work
With;(2) may advantageously facilitate internal colony balance or prevention ecological disturbance;(3) high yield antibacterial substance, acid producing ability are strong;
(4) just has preferable adhesion property from the probiotics of itself enteron aisle, obtains having inhibition pathogen, adjusting enteron aisle micro-
The ecological balance, the bacterial strain for improving immunity of organisms.
The strain of the obtained Lactobacillus brevis is gram-positive bacteria, and characteristic is as follows: the Lactobacillus brevis size is
0.7~1.0 × 2~4 μm, in the arrangement of single or double-strand, bacterium colony is petite, is creamy white, translucent, rough surface,
45 ° of refractive power observations, are evenly distributed, chromatic colour light belt, and microstructure is as shown in Figure 1.
The obtained bifidobacterium longum is Gram-positive bacillus, and characteristic is as follows: size is 0.5-0.8 × 2-8 μ
M, in the shape of a rod, rodlike or bifurcated are V, Y type, arrive macrocolony in the bifidobacterium longum, are in canescence, central uplift, surface is put down
Sliding or mucus shape.The lower 45 ° of refractivities observation of microscope, colony structure is more careful, and edge is irregular, there is fluorescence rag, side
A part of chromatic colour light belt of edge.
The form and dyeing characteristic of the obtained saccharomyces bayanus bacterium: for gram-positive bacteria, 3~6 × 5~14 μ of size
M is in oval, sees Fig. 1.Its colony characteristics is medium macrocolony, white, coarse, round or irregular.The saccharomyces bayanus
Bacterium be it is obligate aerobic, optimum grow initial pH value be 6.0, optimum cultivation temperature be 30 DEG C, shaking flask culture optimum inoculation
Amount is 3%, energy glucose fermentation, maltose, sucrose, fructose and mannitol, azymic galactolipin, gossypose, lactose, nitric acid
It is also Antigen positive hybridomas.
The obtained streptococcus fecalis is Gram-positive bacillus, and characteristic is as follows: streptococcus fecalis is Gram-positive ball
Bacterium, 0.5-1.0 μm of diameter, thallus is single or exists in pairs, irregular heap is also commonly formed, as shown in Figure 1.The excrement chain
The medium bacterium colony bigger than normal of coccus is in canescence, smooth, neat in edge.Its test stone are as follows: should be without miscellaneous bacteria, OD600 value when transferred species
For 1.9-2.4.
The Lactobacillus brevis energy glucose fermentation, arabinose, gluconate, maltose, melezitose and ribose.With
Under seed is produced to 9084 plants of the Lactobacillus brevis of 1st generation, the 10th generation, the 13rd generation production kind of a 1st generation, the 10th generation, the 13rd generation
The bacterium solution viable count of preparation is tested.The metabolite of the bifidobacterium longum is based on acetic acid.Can glucose fermentation, Ah
Draw uncle's sugar, xylose, ribose and lactose.1st generation, the 10th generation, the 13rd generation are reached to bifidobacterium longum production seed below,
Form, cultural character and the viable count of different generation strains are determined.By the basic bacteria of the saccharomyces bayanus bacterium point
It is not seeded to culture medium, stationary culture 18h preparation production seed.Production seed is connected in the medium and passed for 13 generations, observation and survey
Form, cultural character and the viable count of fixed different generation strains, to determine the generation of production strain.By the streptococcus fecalis
N9024 plants of basic bacteria is inoculated with PTYG fluid nutrient medium, 37 DEG C of stationary culture 18h preparation production seeds of streptococcus fecalis respectively.
Production seed is connected in PTYG fluid nutrient medium and passes 13 generations (cultural method is same as above), observes and measure different generation strains
Form, cultural character and viable count, to determine the generation of production strain.Its result is as follows:
Through surveying the bifidobacterium longum, the Bacillus acidi lactici, the streptococcus fecalis, the saccharomyces bayanus bacterium 1st generation, the 10th
Bacterium solution viable count prepared by generation, the 13rd generation production kind 1st generation, the 10th generation, the 13rd generation production seed, produces seed as the result is shown
When reaching for 13 generation, the bifidobacterium longum is not less than 1.0 × 108CFU/mL, and the Bacillus acidi lactici is not less than 1.0 × 108CFU/
ML, shown streptococcus fecalis are not less than 1.0 × 109CFU/mL, and the saccharomyces bayanus bacterium is not less than 1.0 × 108CFU/mL, can
Guarantee being normally carried out for biological products production, shows that the production seed of four kinds of bacterial strains is stablized in 1~13 generation vigor.
The 16SrDNA sequence of the Lactobacillus brevis has the sequential structure as shown in SEQ ID NO.1, the SEQ ID
The sequential structure of NO.1 is specific as follows:
ggatgaacgctggcggcgtgcctaatacatgcaagtcgaacgagttctcgttgatgatcggtgcttgc
ac cgagattcaacatggaacgagtggcggacgggtgagtaacacgtgggtaacctgcccttaagtgggggataac
atttggaaacagatgctaataccgcatagatccaagaaccgcatggttcttggctgaaagatggcgtaagctatc
gcttttggatggacccgcggcgtattagctagttggtgaggtaatggctcaccaaggcgatgatacgtagccgaa
ctgagaggttgatcggccacattgggactgagacacggcccaaactcctacgggaggcagcagtagggaatctt c
cacaatggacgcaagtctgatggagcaacgccgcgtgagtgaagaaggctttcgggtcgtaaaactctgatgtt g
gagaagaatggtcggcagagtaactgttgccggcgtgacggtatccaaccagaaagccacggctaactacgtg cc
agcagccgcggtaatacgtaggtggcaagcgttatccagatttattgggcgtaaagcgagcgcaggcggtttt tt
aagtctgatgtgaaagccctcggcttaaccgaggaagcgcatcggaaactgggaaacttgagtgcagaagag gac
agtggaactccatgtgtagcggtgaaatgcgtagatatatggaagaacaccagtggcgaaggcggctgtct ggtc
tgtaactgacgctgaggctcgaaagcatgggtagcgaacaggattagataccctggtagtccatgccgtaa acga
tgaatgctaggtgttggagggtttccgcccttcagtgccgcagctaacgcattaagcattccgcctggggag tac
gaccgcaaggttgaaactcaaaggaattgacgggggcacgcacaagcggtggagcatgtggtttaattcga agca
acgcgaagaaccttaccaggtcttgacatcttttgatcacttgagagatcaggtttccccttcgggggcaaa atg
acaggtggtgcatggttgtcgtcagctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaaccctt at
gactagttgccagcatttagttgggcactctagtaagactgccggtgacaaaccggaggaaggtggggatga cgt
caaatcatcatgccccttatgacctgggctacacacgtgctacaatggatggtacaacgagttgcgagaccg cga
ggtcaagctaatctcttaaagccattctcagttcggactgtaggctgcaactcgcctacacgaagtcggaatc gc
tagtaatcgcggatcagcacgccgcggtgaatacgttcccgggccttgtacacaccgcccgtcacaccatgag ag
tttgtaacacccgaagccggtggcgtaacccttttagggagcgagccgtct。
The 16SrDNA sequence of the bifidobacterium longum has the sequential structure as shown in SEQ ID NO.2;The SEQ
The sequential structure of ID NO.2 is specific as follows:
caggatgaacgctggcggcgtgcttaacacatgcaagtcgaacgggatccctggcagcttgctgtcggg
gtgagagtggcgaacgggtgagtaatgcgtgaccaacctgccctgtgcaccggaatagctcctggaaacgggtg g
taataccggatgctccgctccatcgcatggtggggtgggaaatgcttttgcggcatgggatggggtcgcgtccta
tcagcttgttggcggggtgatggcccaccaaggcgttgacgggtagccggcctgagagggtgaccggccacatt g
ggactgagatacggcccagactcctacgggaggcagcagtggggaatattgcacaatgggcgcaagcctgat gca
gcgacgccgcgtgcgggatggaggccttcgggttgtaaaccgcttttgttcaagggcaaggcacggtttcgg ccg
tgttgagtggattgttcgaataagcaccggctaactacgtgccagcagccgcggtaatacgtagggtgcgag cgt
tatccggatttattgggcgtaaagggctcgtaggcggttcgtcgcgtccggtgtgaaagtccatcgcctaacg gt
ggatctgcgccgggtacgggcgggctggagtgcggtaggggagactggaattcccggtgtaacggtggaatg tgt
agatatcgggaagaacaccaatggcgaaggcaggtctctgggccgtcactgacgctgaggagcgaaagcg tgggg
agcgaacaggattagataccctggtagtccacgccgtaaacggtggatgctggatgtggggccctttcca cgggt
cccgtgtcggagccaacgcgttaagcatcccgcctggggagtacggccgcaaggctaaaactcaaaga aattgac
gggggcccgcacaagcggcggagcatgcggattaattcgatgcaacgcgaagaaccttacctgggct tgacatgt
gccggatcgccgtggagacacggtttcccttcggggccggttcacaggtggtgcatggtcgtcgtcag ctcgtgt
cgtgagatgttgggttaagtcccgcaacgagcgcaaccctcgccgcatgttgccagcgggtgatgccg ggaactc
atgtgggaccgccggggtcaactcggaggaaggtggggatgacgtcagatcatcatgccccttacgt ccagggct
tcacgcatgctacaatggccggtacaacgcggtgcgacacggtgacgtggggcggatcgctgaaa accggtctca
gttcggatcgcagtctgcaactcgactgcgtgaaggcggagtcgctagtaatcgcggatcagcaa cgccgcggtg
aatgcgttcccgggccttgtacacgccgcccgtcaagtcatgaaagtgggtagcacccgaagcc ggtggcccgac
ccttgtggggggagccgtctaaggtgaga。
The 26S rDNA sequence of the saccharomyces bayanus bacterium has the sequential structure as shown in SEQ ID NO.3;The SEQ ID
The sequential structure of NO.3 is specific as follows:
atgcttagtacggcgagtgagcggcaaaagctcaaatttgaaatctggtaccttcggtgcccgagttg
ta atttggagagggcaactttggggccgttccttgtctatgttccttggaacaggacgtcatagagggtgagaat
ccc gtgtggcgaggagtgcggttctttgtaaagtgccttcgaagagtcgagttgtttgggaatgcagctctaagt
gggt ggtaaattccatctaaagctaaatattggcgagagaccgatagcgaacaagtacagtgatggaaagatgaa
aa gaactttgaaaagagagtgaaaaagtacgtgaaattgttgaaagggaagggcatttgatcagacatggtgttt
tg tgccctctgctccttgtgggtaggggaatctcgcatttcactgggccagcatcagttttggtggcaggataaa
tcca taggaatgtagcttgcctcggtaagtattatagcctgtgggaatactgccagctgggactgaggactgcga
cgta agtcaaggatgctggcataatggttatatgccgcccgtcttgaaacacg。
The 16SrDNA sequence of the streptococcus fecalis has the sequential structure as shown in SEQ ID NO.4.The SEQ ID
The sequential structure of NO.4 is specific as follows:
gaacgctggcggcgtgcctaatacatgcaagtagaacgctgaagagaggagcttgctcttcttggatga
gttgcgaacgggtgagtaacgcgtaggtaacctgccttgtagcgggggataactattggaaacgatagctaatac
cgcataacaatggatgacacatgtcatttatttgaaaggggcaattgctccactacaagatggacctgcgttgtat
tagctagtaggtgaggtaatggctcacctaggcgacgatacatagccgacctgagagggtgatcggccacactg g
gactgagacacggcccagactcctacgggaggcagcagtagggaatcttcggcaatgggggcaaccctgacc gag
caacgccgcgtgagtgaagaaggttttcggatcgtaaagctctgttgtaagtcaagaacgggtgtgagagtg gaa
agttcacactgtgacggtagcttaccagaaagggacggctaactacgtgccagcagccgcggtaatacgta ggtc
ccgagcgttgtccggatttattgggcgtaaagcgagcgcaggcggtttgataagtctgaagttaaaggctgt ggc
tcaaccatagttcgctttggaaactgtcaaacttgagtgcagaaggggagagtggaattccatgtgtagcgg tga
aatgcgtagatatatggaggaacaccggtggcgaaagcggctctctggtctgtaactgacgctgaggctcga aag
cgtggggagcgaacaggattagataccctggtagtccacgccgtaaacgatgagtgctaggtgttggatcct ttc
cgggattcagtgccgcagctaacgcattaagcactccgcctggggagtacgaccgcaaggttgaaactcaaa gga
attgacgggggcccgcacaagcggtggagcatgtggtttaattcgaagcaacgcgaagaaccttaccaggt cttg
acatcccgatgctatttctagagatagaaagttacttcggtacatcggtgacaggtggtgcatggttgtcgtc ag
ctcgtgtcgtgagatgttgggttaagtcccgcaacgagcgcaacccctattgttagttgccatcattcagttggg
cactctagcgagactgccggtaataaaccggaggaaggtggggatgacgtcaaatcatcatgccccttatgacct
gggctacacacgtgctacaatggttggtacaacgagttgcgagtcggtgacggcgagctaatctcttaaagccaa
tctcagttcggattgtaggctgcaactcgcctacatgaagtcggaatcgctagtaatcgcggatcagcacgccgcg
gtgaatacgttcccgggccttgtacacaccgcccgtcacaccacgagagtttgtaacacccgaagt。
The preparation of 2 complex microbial inoculum of embodiment
The complex microbial inoculum of the present embodiment, including Lactobacillus brevis described in embodiment 1, bifidobacterium longum, shellfish ferment
Female bacterium and streptococcus fecalis.
Preparation method is as follows:
A, Lactobacillus brevis freeze-dried powder is prepared;
(1) Lactobacillus brevis is taken, the 50L of the LYT fermentation medium equipped with 35L is seeded to according to 1% inoculum concentration
In fermentor, under conditions of temperature is 37 DEG C, the tank pressure of revolving speed 50rpm, fermentor is 0.05Mpa, ferment 18h, right
Number growth period obtains one grade fermemtation liquid;Then, the one grade fermemtation liquid is taken, is seeded to according to 8% inoculum concentration and is sent out equipped with LYT
In the fermentor of ferment culture medium, under conditions of temperature is 37 DEG C, the tank pressure of revolving speed 150rpm, fermentor is 0.05Mpa,
Anaerobic culturel 20h obtains the second order fermentation liquid of logarithmic phase growth;The second order fermentation liquid is taken again, according to 7.5% inoculum concentration
It is seeded in LYT fermentation medium, in the condition that temperature is 37 DEG C, the tank pressure of revolving speed 150rpm, fermentor is 0.05Mpa
Under, Anaerobic culturel for 24 hours, obtains the three grade fermemtation liquid of the Lactobacillus brevis of logarithmic phase growth.
Wherein, the pH value of the LYT fermentation medium is 7.0, specifically includes the raw material of following parts by weight: peptone 2.0
Parts by weight;2.0 parts by weight of yeast extract;2.0 parts by weight of glucose;4.0 parts by weight of trace salt, 0.05 weight of L-cysteine salt
Measure part;
The trace salt includes the following raw material: calcium chloride 0.2g/L, magnesium sulfate 0.48g/L, sodium bicarbonate 10g/L, phosphoric acid
Potassium dihydrogen 1.0g/L, dipotassium hydrogen phosphate 1.0g/L, sodium chloride 2.0g/L.
Since Lactobacillus brevis is facultative anaerobic bacteria, Anaerobic culturel is grown more preferable, therefore, using described in above method culture
Lactobacillus brevis, strain activity, flourish situation are more excellent.It further include in preparation institute as the preferred implementation of the present embodiment
The step of testing when stating one grade fermemtation liquid, second order fermentation liquid, three grade fermemtation liquid, it is specific as follows: to obtain the level-one hair
Zymotic fluid should be pure, and OD600Value is 1.8-2.3;The obtained second order fermentation liquid should be pure, and OD600Value is 1.8-2.4;?
The three grade fermemtation liquid arrived should be pure.
(2) fermentation liquid that fermentation obtains in step (1) is taken, is placed it in centrifuge, revolving speed 8000r/min,
It is centrifuged 60min, collects bacterium mud;
(3) be added the protective agent into bacterium mud obtained in step (2), the protective agent be sucrose, skimmed milk power and
Gelatin is mixed according to the weight ratio of 5:3:1.The sucrose, the skimmed milk power, the gelatin are uniformly mixed, through 115
DEG C sterilizing 30min, after being cooled to room temperature, aseptically with the bacterium mud according to 3:1 weight ratio mix, bacterium is made
Suspension, pre-freeze 3h at a temperature of placing it in -40 DEG C, distil 15h at a temperature of being subsequently placed in -15 DEG C, then is placed in 25 DEG C of temperature
The lower 2h that distils of degree makes the water content of the bacterium mud less than 5% to get Lactobacillus brevis freeze-dried powder after placing 2h under vacuum.
B, bifidobacterium longum freeze-dried powder is prepared
(1) take the bifidobacterium longum, temperature be 37 DEG C at, initial pH value be 7.5 solidification cow's milk in culture 36~
48 hours, as the preferred implementation of the present embodiment, the bifidobacterium longum was seeded to by 3% inoculum concentration as culture
On the solidification cow's milk of base, and the culture by the way of shaking flask culture;
(2) fermentation liquid that fermentation obtains in step (1) is taken, is placed it in centrifuge, revolving speed 8000r/min,
It is centrifuged 30min, collects bacterium mud;
(3) be added the protective agent into bacterium mud obtained in step (2), the protective agent be sucrose, skimmed milk power and
Gelatin is mixed according to the weight ratio of 5:3:1.The sucrose, the skimmed milk power, the gelatin are uniformly mixed, through 115
DEG C sterilizing 30min, after being cooled to room temperature, aseptically with the bacterium mud according to 3:1 weight ratio mix, bacterium is made
Suspension, pre-freeze 3h at a temperature of placing it in -40 DEG C, distil 15h at a temperature of being subsequently placed in -15 DEG C, then is placed in 25 DEG C of temperature
The lower 2h that distils of degree makes the water content of the bacterium mud less than 5% to get bifidobacterium longum freeze-dried powder after placing 2h under vacuum.
C, saccharomyces bayanus bacterium freeze-dried powder is prepared;
(1) bacterium solution for taking the logarithmic growth phase obtained after saccharomyces bayanus bacterium culture 6h-12h, as primary seed solution,
Primary seed solution is inoculated in fermentation medium according to the inoculum concentration of 4-10%, temperature be 28-32 DEG C, revolving speed 150-
Under conditions of 200rpm, 24-36h is cultivated, one grade fermemtation liquid is obtained;Then, the one grade fermemtation liquid is taken, according to 4-10%'s
Inoculum concentration is seeded in fermentation medium, under conditions of temperature is 28-32 DEG C, revolving speed is 100-180rpm, cultivates 4-6h,
Obtain second order fermentation liquid;The second order fermentation liquid is taken again, is seeded in fermentation medium according to the inoculum concentration of 4-10%, in temperature
Under conditions of degree is 28-32 DEG C, revolving speed is 150-250rpm, 14-16h is cultivated, three grade fermemtation liquid is obtained.
Wherein, the pH value of the fermentation medium is 6.0-6.5, and including following ingredient: yeast extract, peptone, Portugal
Grape sugar and trace salt.As the preferred implementation of the present embodiment, the fermentation medium includes the raw material of following parts by weight: 5
Parts by weight yeast extract, 10 parts by weight peptones, 5 parts by weight glucose, 5 parts by wt NaCl, 1 parts by weight trace salt.It is described
Trace salt is in calcium chloride, magnesium sulfate, sodium bicarbonate, potassium dihydrogen phosphate, dipotassium hydrogen phosphate and sodium chloride according to 1:2:6:4:1:
2 weight ratio mixes.
(2) fermentation liquid that fermentation obtains in step (1) is taken, is placed it in centrifuge, revolving speed 8000r/min,
It is centrifuged 30min, collects bacterium mud;
(3) be added the protective agent into bacterium mud obtained in step (2), the protective agent be sucrose, skimmed milk power and
Gelatin is mixed according to the weight ratio of 5:3:1.The sucrose, the skimmed milk power, the gelatin are uniformly mixed, through 115
DEG C sterilizing 30min, after being cooled to room temperature, aseptically with the bacterium mud according to 3:1 weight ratio mix, bacterium is made
Suspension, pre-freeze 3h at a temperature of placing it in -40 DEG C, distil 15h at a temperature of being subsequently placed in -15 DEG C, then is placed in 25 DEG C of temperature
The lower 2h that distils of degree makes the water content of the bacterium mud less than 5% to get saccharomyces bayanus bacterium freeze-dried powder after placing 2h under vacuum.
D, streptococcus fecalis freeze-dried powder is prepared;
(1) streptococcus fecalis is taken, is seeded in one grade fermemtation culture medium and cultivates according to 1% inoculum concentration, in temperature
Under conditions of being 100-180rpm for 37 ± 3 DEG C, revolving speed, ferment 12-14h, obtains one grade fermemtation liquid;Then, the level-one is taken
Fermentation liquid is seeded in second order fermentation culture medium according to the inoculum concentration of 5-10%, is 37 ± 3 DEG C, revolving speed 100- in temperature
Under conditions of 180rpm, 4-6h is cultivated, second order fermentation liquid is obtained;The second order fermentation liquid is taken again, according to the inoculum concentration of 5-12%
It is seeded in three grade fermemtation culture medium, under conditions of temperature is 37 ± 3 DEG C, revolving speed is 150-250rpm, cultivates 14-16h,
Obtain three grade fermemtation liquid.Wherein, the one grade fermemtation culture medium, the second order fermentation culture medium, the three grade fermemtation culture medium
For same culture medium, pH value is 7.0-7.4, and includes following component: 1.5 parts by weight of peptone;Yeast extract powder
0.6 parts by weight;2 parts by weight of glucose;0.05 parts by weight of soluble starch;0.5 parts by weight of sodium chloride;L-cysteine salt
0.05 parts by weight;20 parts by weight of Tomato juice;0.01 parts by weight of Tween-80;0.5 parts by weight of lactoalbumin hydrolysate;2 weight of agar powder
Measure part.
(2) fermentation liquid that fermentation obtains in step (1) is taken, is placed it in centrifuge, revolving speed 8000r/min,
It is centrifuged 30min, collects bacterium mud;
(3) be added the protective agent into bacterium mud obtained in step (2), the protective agent be sucrose, skimmed milk power and
Gelatin is mixed according to the weight ratio of 5:3:1.The sucrose, the skimmed milk power, the gelatin are uniformly mixed, through 115
DEG C sterilizing 30min, after being cooled to room temperature, aseptically with the bacterium mud according to 3:1 weight ratio mix, bacterium is made
Suspension, pre-freeze 3h at a temperature of placing it in -40 DEG C, distil 15h at a temperature of being subsequently placed in -15 DEG C, then is placed in 25 DEG C of temperature
The lower 2h that distils of degree makes the water content of the bacterium mud less than 5% to get streptococcus fecalis freeze-dried powder after placing 2h under vacuum.
E, the mixing of four kinds of freeze-dried powders;
By the freeze-drying of the freeze-dried powder, the bifidobacterium longum of the Lactobacillus brevis being prepared in step A, B, C, D
The freeze-dried powder of powder, the freeze-dried powder of the saccharomyces bayanus bacterium and the streptococcus fecalis, by four kinds of freeze-dried powders according to the weight of 1:1:1:1
Than be uniformly mixed to get.
The preparation of 3 complex microbial inoculum of embodiment
The complex microbial inoculum of the present embodiment, including Lactobacillus brevis described in embodiment 1, bifidobacterium longum, shellfish ferment
Female bacterium and streptococcus fecalis.Preparation method is as follows:
The preparation method of the complex microbial inoculum, specifically comprises the following steps:
(1) Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis are taken, is fermented respectively
Culture, obtains the fermentation liquid of the Lactobacillus brevis, the fermentation liquid of the bifidobacterium longum, the fermentation liquid of the saccharomyces bayanus bacterium, institute
State the fermentation liquid of streptococcus fecalis;
(2) four kinds of fermentation liquids that fermentation obtains in step (1) are taken, placing it in revolving speed respectively is 8000-12000 r/min
Under, it is centrifuged 10-30min, bacterium mud is collected, obtains four kinds of bacterium muds;
(3) protective agent, the protective agent and the bacterium mud are separately added into bacterium mud obtained in step (2)
Weight ratio is 3:1, is uniformly mixed, pre-freeze 3h at a temperature of placing it in -40 DEG C distils at a temperature of being subsequently placed in -15 DEG C
15h, then the 2h that distils at a temperature of being placed in 25 DEG C make the water content of the bacterium mud less than 5%, obtain after placing 2h under vacuum
The freeze-dried powder of the Lactobacillus brevis, the freeze-dried powder of the bifidobacterium longum, the saccharomyces bayanus bacterium freeze-dried powder and the excrement hammer
The freeze-dried powder of bacterium, by four kinds of freeze-dried powders be uniformly mixed to get.Wherein, the protective agent is that sucrose, skimmed milk power and gelatin are pressed
It is mixed according to the weight ratio of 5:3:1.
The preparation of 4 bifidobacterium longum freeze-dried powder of embodiment
The complex microbial inoculum of the present embodiment, including Lactobacillus brevis described in embodiment 1, bifidobacterium longum, shellfish ferment
Female bacterium and streptococcus fecalis.Preparation method is as follows:
It is added and protects into the Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis respectively
Agent is protected, is uniformly mixed, pre-freeze 1-3h at a temperature of placing it in -30~-50 DEG C is subsequently placed at a temperature of -10~-20 DEG C
Distil 10-20h, then the 10-20h that distils at a temperature of being placed in -10~-25 DEG C, then in 20-30 DEG C of at a temperature of secondary distillation 1-
5h, under vacuum to get the freeze-dried powder of the Lactobacillus brevis, the freeze-dried powder of the bifidobacterium longum, the shellfish after placement 1-5h
The freeze-dried powder of saccharomycete and the freeze-dried powder of the streptococcus fecalis, by four kinds of freeze-dried powders be uniformly mixed to get.
In the present embodiment, the protective agent is skimmed milk power, be alternative implementation as the present embodiment, the guarantor
Shield agent also can be replaced skimmed milk power, maltose, sucrose, soluble starch, mannitol, sodium glutamate, L-cysteine, bright
One of glue is a variety of.
Effete test embodiment
Experiment one, the preparation storage life test of the complex microbial inoculum
Take the Lactobacillus brevis that deposit number is CGMCC NO.16125, deposit number be CGMCC NO.16126
The bifidobacterium longum, deposit number be CGMCC NO.16127 the saccharomyces bayanus bacterium, deposit number CGMCC
The streptococcus fecalis of NO.16128, basic bacteria freeze-dried powder is saved under the conditions of -80 DEG C, and storage life is 2 years, every two years
Detection is primary.
Wherein, the method for count plate is specific as follows:
It is sterile to weigh bifidobacterium longum preparation described in 3g, 27mL fluid nutrient medium or physiological saline is added, sufficiently shakes up
(shaken and beaten with several glass marbles) is made 10 times afterwards and is serially diluted, and acceptable diluent degree is selected to be inoculated with.It is selectively cultivated using LBS
Each dilution of base, bacterium is inoculated with 3 plates, and rapid pivotal plate by 0.2mL, keeps bacterium solution even in media surface stream.
After culture 48 hours, the bacterial growth situation on each plate is observed, and count.When the clump count on each plate is less than 10
Or when being greater than 300, last dilution should be readjusted, is redeterminated.It is calculated according to the following formula according to 3 plate total plate counts
Viable count:
Testing result is as follows:
Bacterial strain saves the viable count of different time at -80 DEG C
Bacterial strain saves the viable count of different time at 4 DEG C
Bacterial strain saves the viable count of different time at 25 DEG C
Test the viable count comparative experiments of two kinds of bacterial strains of two, complex microbial inoculum
The Lactobacillus brevis freeze-dried powder being prepared in Example 2, is denoted as CGMCC No.16125 group;In taking
Deposit number is the Lactobacillus brevis of CGMCC No.5760 in state patent document CN102660477A, according to the method in the document
Freeze-dried powder is prepared, is denoted as CGMCC No.5760 group;It is protected at normal temperature according to the bacterium powder that the method for experiment one detects two groups
Deposit the viable count of different time.
Its experimental result is as follows:
The bifidobacterium longum freeze-dried powder being prepared in Example 2, is denoted as CGMCC No.
16126 groups;Take the long bifid that deposit number is CGMCC No.6283 in Chinese patent literature CN104120093A
Freeze-dried powder is prepared according to the method in embodiment 2 in bacillus, is denoted as CGMCC No.6283 group;According to the method for experiment one
Detect the viable count that two groups of bacterium powder saves different time at normal temperature.
Its experimental result is as follows:
Experiment three, the acid and bile salt tolerance characteristic test of bacterial strain
In order to simulate the intracorporal gastrointestinal tract environment of animal, simulated gastric fluid and simulated intestinal fluid are prepared, is carried out external acidproof resistance to
The research of gallbladder performance.Furthermore action time is also one of the major issue be considered as when such test.Due to depositing for cholate
In the permeability for changing thallus outer membrane, so generating inhibition, killing effect to probiotics, and then the survival of probiotics is influenced.
(1) Lactobacillus brevis
Stomach juice-resistant test: taking deposit number is the Lactobacillus brevis of CGMCC No.16125, using simulated gastric fluid as base
Plinth, has then been activated the liquid culture in two generations by the access of 10% inoculum concentration, and 37 DEG C of stationary cultures take respectively at 0,1,2,4h
Sample measures viable count.
The salt test of resistance to cholic acid: taking deposit number is the Lactobacillus brevis of CGMCC No.16125, using simulated intestinal fluid as base
0.3% No. 3 cholate are added in plinth, then activate the Bifidobacterium liquid culture in two generations according to 10% inoculum concentration access,
37 DEG C of stationary cultures are measured by sampling viable count, and calculate survival rate respectively at 0,1,2,4h.
The testing result of stomach juice-resistant is as follows:
The testing result of resistance to cholate is as follows:
(2) bifidobacterium longum
Stomach juice-resistant test: taking deposit number is the bifidobacterium longum of CGMCC No.16126, is placed in simulated gastric fluid
In, 37 DEG C of stationary culture 2h are measured by sampling viable count, and calculate survival rate.
The salt test of resistance to cholic acid: taking deposit number is the bifidobacterium longum of CGMCC No.16126, is with simulated intestinal fluid
0.3% cholate is added in basis thereto, and then the bifidobacterium longum is placed in one, in 37 DEG C of stationary culture 2h, sampling
Viable count is measured, and calculates survival rate.
The testing result of stomach juice-resistant is survival rate 66.0%;The testing result of resistance to cholate is survival rate 51.1%.
(3) streptococcus fecalis
Stomach juice-resistant test: taking deposit number is the streptococcus fecalis of CGMCC No.16128, is placed in simulated gastric fluid,
37 DEG C of stationary cultures 0h, 1h, 2h, 4h are measured by sampling viable count, and calculate survival rate.
Its experimental result is as follows:
Time | 0h | 1h | 2h | 4h |
Viable bacteria rate (%) | 100 | 90.0 | 87.7 | 73.8 |
The salt test of resistance to cholic acid: taking deposit number is the streptococcus fecalis of CGMCC No.16128, using simulated intestinal fluid as base
0.3% cholate is added in plinth thereto, and then the streptococcus fecalis is placed in one, in 37 DEG C of stationary cultures 0h, 1h, 2h, 4h,
Viable count is measured by sampling, and calculates survival rate.Its experimental result is as follows:
Time | 0h | 1h | 2h | 4h |
Viable bacteria rate (%) | 100 | 83.6 | 73.6 | 65.4 |
Also commercially available three kinds of streptococcus fecalis are tested using the above method in this experiment, commercially available three kinds of excrement hammers
Bacterium simulation hydrochloric acid, cholate environment in cultivate 4h after, viable bacteria rate is below 43%.It can be seen that preservation of the invention is compiled
Number for CGMCC No.16128 the streptococcus fecalis acidproof and bile tolerance function admirable.
(4) saccharomyces bayanus bacterium
Stomach juice-resistant test: taking deposit number is the saccharomyces bayanus bacterium of CGMCC No.16127, is accessed by 10% inoculum concentration
In simulated gastric fluid, 37 DEG C of stationary cultures 0h, 1h, 2h, 4h are measured by sampling viable count, and calculate survival rate.Its experimental result is such as
Under:
Time | 0h | 1h | 2h | 4h |
Viable bacteria rate (%) | 100 | 100 | 93 | 76.7 |
The salt test of resistance to cholic acid: taking deposit number is the saccharomyces bayanus bacterium of CGMCC No.16127, using simulated intestinal fluid as base
Plinth, then 0.3% cholate is added thereto, then the saccharomyces bayanus bacterium is accessed wherein according to 10% inoculum concentration, quiet at 37 DEG C
Culture 0h, 1h, 2h, 4h are set, viable count is measured by sampling, and calculate survival rate.Its experimental result is as follows:
Time | 0h | 1h | 2h | 4h |
Viable bacteria rate (%) | 100 | 81.4 | 72.5 | 57.5 |
Also commercially available three kinds of saccharomyces bayanus bacterium are tested using the above method in this experiment, commercially available three kinds of saccharomyces bayanus
Bacterium simulation hydrochloric acid, cholate environment in cultivate 4h after, viable bacteria rate is below 51%.It can be seen that preservation of the invention is compiled
Number for CGMCC No.16127 the saccharomyces bayanus bacterium acidproof and bile tolerance function admirable.
Experiment four inhibits pathogen capacity experimental
(1) Lactobacillus brevis: taking deposit number of the invention is the Lactobacillus brevis of CGMCC No.16125, Yi Jizhong
Deposit number is the Lactobacillus brevis of CGMCC No.5760 in state patent document CN102660477A, detects it respectively to virulent big
The suppression of enterobacteria EC82-86, virulent salmonella C79-14, staphylococcus saprophyticus SS9084 (being provided by Chinese medicine inspecting institute)
Bacterium radius, and record.Its testing result is as follows:
(2) bifidobacterium longum: take deposit number of the invention be CGMCC No.16126 the bifidobacterium longum, in
Deposit number is the bifidobacterium longum of CGMCC No.6283 in state patent document CN104120093A, then takes and supervised by Chinese drug
Examine provided pathogenic bacteria: pathogenic virulent Escherichia coli 44365, pathogenic virulent salmonella C-79-14, pathogenic virulent
Salmonella C-79-20.Each bacterial strain is detected respectively to the antibacterial radius of each pathogenic bacteria, and is recorded.Its testing result is as follows:
(3) streptococcus fecalis: taking deposit number of the invention is the streptococcus fecalis, commercially available of CGMCC No.16128
Streptococcus fecalis, then take and provided pathogenic bacteria: pathogenic virulent Escherichia coli 44365, pathogenic virulent sand are supervised by Chinese drug
Door Salmonella C-79-14, pathogenic virulent salmonella C-79-20.Each bacterial strain is detected respectively to the antibacterial radius of each pathogenic bacteria,
And it records.Its testing result is as follows:
(4) complex microbial inoculum in embodiment 2: detecting according to the method described above, to the antibacterial radius of each pathogenic bacteria,
And it records.Its testing result is as follows: Escherichia coli 38mm, salmonella 32mm, staphylococcus 37mm.It can be seen that of the invention
It, can be with mutualism without mutual antagonism between four kinds of bacterial strains of the complex microbial inoculum.
The influence experiment of experiment five, protective agent to freeze-dried powder technique
This experiment is investigated and is acted on protectant frozen-dried protective using survival rate as index.In the way of in embodiment 2
Prepare the complex microbial inoculum, difference is only that: protective agent is replaced with respectively skimmed milk power, maltose, sucrose, can
Bifidobacterium longum is prepared in soluble starch, sodium glutamate, L-cysteine, gelatin, mannitol, and that tests respectively is micro-
Biological compound fungi agent saves the survival rate after 30 days at normal temperature.
It can be seen that the effect is unsatisfactory as protectant for single ingredient, and protective agent is to the Bifidobacterium
Protecting effect differs greatly.In order to verify the stability of the technique, experimental verification three times is carried out to the scheme in embodiment 2, it is living
Bacterium rate resultant error rate < 4%, it was demonstrated that result is reliable and stable.
Complex microbial inoculum is prepared in the way of in embodiment 2, difference is only that: protective agent is replaced with respectively
Three kinds of skimmed milk power, sucrose, gelatin ingredients are mixed according to the weight ratio of 1:1:1, and are denoted as first group;By defatted milk
Three kinds of powder, sucrose, gelatin ingredients mix according to the weight ratio of 1:3:2, and are denoted as second group;By skimmed milk power, sucrose,
Three kinds of ingredients of gelatin are mixed according to the weight ratio of 1:5:3, and are denoted as third group;By skimmed milk power, sucrose, three kinds of gelatin
Ingredient is mixed according to the weight ratio of 2:1:2, and is denoted as the 4th group;By skimmed milk power, sucrose, three kinds of ingredients of gelatin according to
The weight ratio of 2:3:3 mixes, and is denoted as the 5th group;By three kinds of skimmed milk power, sucrose, gelatin ingredients according to 2:5:1's
Weight ratio mixing, and it is denoted as the 6th group;Three kinds of skimmed milk power, sucrose, gelatin ingredients are mixed according to the weight ratio of 3:1:3
It closes, and is denoted as the 7th group;By skimmed milk power, sucrose, three kinds of ingredients of gelatin according to 3:3:2 weight ratio mix, and by its
It is denoted as the 8th group;The complex microbial inoculum that embodiment 2 is prepared is denoted as the 9th group.Above-mentioned each group is tested respectively to obtain
Bifidobacterium longum freeze-dried powder save the survival rate after 30 days at normal temperature.
Its testing result is as follows:
Group | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
Viable bacteria rate (%) | 53.8 | 65.9 | 71.6 | 64.4 | 83.0 | 84.4 | 64.1 | 74.7 | 91.7 |
Experiment six, the complex microbial inoculum are to small white mouse safety testing
The small white mouse of 20-22g is taken, cleaning grade test uses small white mouse 40, divides 4 groups, every group 10, wherein 1-3 group is given
The active bacteria formulation for the complex microbial inoculum being prepared in embodiment 2, dosage are not less than 1.0 × 107CFU gives
The medicine period is 3 days, after administration, observes the clinical symptoms of all small white mouses, evaluates test result.
The clinical settings such as spirit, feeding, drinking-water, growth, weight gain of small white mouse after observation medicine feed, and observation experimental period
Between animal whether have an adverse reaction relevant to drug, such as breathing, abnormal behavior, spirit inhibits and the abnormal variation feelings of defecation
Condition.And the weight for recording every group of small white mouse on the 13rd day that the same day (the 1st day) and experiment terminate before administration, calculate small white mouse
Average weight increasing a day.
Its experimental result is as follows:
Each group small white mouse during test is all strong to live, and spirit is good, and honey stomach, the fur colour of skin is normal, defecation urination
Color form is normal, no other abnormal clinical symptoms, without sick and dead show.
It weighs within the 13rd day, and calculates to every group of small white mouse after the same day (the 1st day), experiment before administration
Each group average daily gain.As a result it see the table below:
Find that the small white mouse Average weight increasing a day of 3 experimental groups is apparently higher than the 4th group of blank control, shows this hair from table
The bright complex microbial inoculum has obvious effect of gain to small white mouse, and it is qualified that safety examination is administered.
Experiment seven, the complex microbial inoculum test the improvement of dog intestinal bacilli illness Diarrhea Model
This test, as induced drug, leads to beasle dog enteric flora disturbance, structure by being administered continuously using cefalexin
Test dog antibiotic-associated diarrhea is built, specifically comprises the following steps: to take for 3.5~4 monthly ages, 5.0~6.5kg's of weight is common
Grade test uses beasle dog 25, wherein 5, as a control group, in addition 20 in such a way that gradient increases induced drug dosage,
Continuously give antibiotic induction, building test dog intestinal bacilli illness Diarrhea Model, antibiotic induce 15~20 days, structure mould at
Function.Induce through antibiotic 20 beasle dogs are divided into high dose group, middle dose group, low dose group, model group, to high dose
Group, middle dose group, low dose group give the active bacteria formulation of the bifidobacterium longum of the present invention of high, medium and low dosage respectively,
Model group is not administered, and dosage period is 6~8 days, after administration, observes the clinical symptoms of all dogs only.
Its experimental result is as follows:
Beasle dog weight is an index that is intuitive, easily investigating, and closely related with many factors.To pretherapy and post-treatment ratio
The weight of lattice dog is analyzed.Different groups of beasle dog weight is compared two-by-two after modeling, the average body of dog is tested between group
Weight P > 0.05 illustrates to influence beasle dog changes of weight using Antibiotics model little.It is compound continuously to give the microorganism
After microbial inoculum 7 days, model group, low, middle and high dose groups are compared into P > 0.05 two-by-two, illustrates the microbial inoculum of various dose to test dog
Weight influence it is not significant.
Before modeling, each group beasle dog is vivaciously active, and coat is flat and smooth, excrement dry forming, more normally.Modeling knot
Shu Shi, control group beasle dog diet is normal, and action is active, defecation frequency rule, excrement dry forming.Through antibiotic induction
The dilute wet, agility of stool, which gradually occurs, in test dog to be reduced, occasionally has the symptoms such as anorexia or out of strength, vomiting, is belonged to antibiotic and is excessively caused
Classical symptom caused by intestinal bacilli illness.
Preparation is as follows: the influence testing result of test dog excrement state
Wherein, excrement state: -- formed stool;+ forming but moisture it is slightly more;++ sticky half congealed loose stools;+++ watery stool.
After continuously giving active bacteria formulation 5 days, by dog clinical symptoms, excrement situation and bacteria detection as a result, statistics is different
Curative effect of the dosage group to puppy intestinal bacilli illness disease.Its testing result is as follows:
Group | Number of animals | It cures | It is effective | Effectively | In vain | It is efficient |
Low dose group | 5 | 2 | 1 | 4 | 1 | 80% |
Middle dose group | 5 | 4 | 1 | 5 | 0 | 100% |
High dose group | 5 | 4 | 1 | 5 | 0 | 100% |
Complex microbial inoculum 2 times a day, is continuously fed 5 days with 2.0g//times, can be alleviated puppy because of enterobacteriaceae
Symptom of diarrhea caused by group's deficiency disorder, promotes dog only to restore colony balance.It can be seen that microbial composite bacteria of the present invention
It, can be with mutualism without mutual antagonism between four kinds of bacterial strains of agent.And the bifidobacterium longum, the Bacillus acidi lactici, institute
Stating streptococcus fecalis has powerful antagonism to pathogen, and then the complex microbial inoculum for forming four kinds of bacterial strains
Have the function of good recuperating gastrointestinal tract health, improve immunity.
Obviously, the above embodiments are merely examples for clarifying the description, and does not limit the embodiments.
For those of ordinary skill in the art, other various forms of changes can also be made on the basis of the above description
Change or changes.There is no necessity and possibility to exhaust all the enbodiments.And obvious change extended from this
Change or changes still within the protection scope of the invention.
SEQUENCE LISTING
<110>Tan Ying
<120>a kind of complex microbial inoculum and its preparation method and application
<130> 2018
<160> 4
<170> PatentIn version 3.3
<210> 1
<211> 1469
<212> DNA
<213>Lactobacillus brevis
<400> 1
ggatgaacgc tggcggcgtg cctaatacat gcaagtcgaa cgagttctcg ttgatgatcg 60
gtgcttgcac cgagattcaa catggaacga gtggcggacg ggtgagtaac acgtgggtaa 120
cctgccctta agtgggggat aacatttgga aacagatgct aataccgcat agatccaaga 180
accgcatggt tcttggctga aagatggcgt aagctatcgc ttttggatgg acccgcggcg 240
tattagctag ttggtgaggt aatggctcac caaggcgatg atacgtagcc gaactgagag 300
gttgatcggc cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtagg 360
gaatcttcca caatggacgc aagtctgatg gagcaacgcc gcgtgagtga agaaggcttt 420
cgggtcgtaa aactctgatg ttggagaaga atggtcggca gagtaactgt tgccggcgtg 480
acggtatcca accagaaagc cacggctaac tacgtgccag cagccgcggt aatacgtagg 540
tggcaagcgt tatccagatt tattgggcgt aaagcgagcg caggcggttt tttaagtctg 600
atgtgaaagc cctcggctta accgaggaag cgcatcggaa actgggaaac ttgagtgcag 660
aagaggacag tggaactcca tgtgtagcgg tgaaatgcgt agatatatgg aagaacacca 720
gtggcgaagg cggctgtctg gtctgtaact gacgctgagg ctcgaaagca tgggtagcga 780
acaggattag ataccctggt agtccatgcc gtaaacgatg aatgctaggt gttggagggt 840
ttccgccctt cagtgccgca gctaacgcat taagcattcc gcctggggag tacgaccgca 900
aggttgaaac tcaaaggaat tgacgggggc acgcacaagc ggtggagcat gtggtttaat 960
tcgaagcaac gcgaagaacc ttaccaggtc ttgacatctt ttgatcactt gagagatcag 1020
gtttcccctt cgggggcaaa atgacaggtg gtgcatggtt gtcgtcagct cgtgtcgtga 1080
gatgttgggt taagtcccgc aacgagcgca acccttatga ctagttgcca gcatttagtt 1140
gggcactcta gtaagactgc cggtgacaaa ccggaggaag gtggggatga cgtcaaatca 1200
tcatgcccct tatgacctgg gctacacacg tgctacaatg gatggtacaa cgagttgcga 1260
gaccgcgagg tcaagctaat ctcttaaagc cattctcagt tcggactgta ggctgcaact 1320
cgcctacacg aagtcggaat cgctagtaat cgcggatcag cacgccgcgg tgaatacgtt 1380
cccgggcctt gtacacaccg cccgtcacac catgagagtt tgtaacaccc gaagccggtg 1440
gcgtaaccct tttagggagc gagccgtct 1469
<210> 2
<211> 1448
<212> DNA
<213>bifidobacterium longum
<400> 2
caggatgaac gctggcggcg tgcttaacac atgcaagtcg aacgggatcc ctggcagctt 60
gctgtcgggg tgagagtggc gaacgggtga gtaatgcgtg accaacctgc cctgtgcacc 120
ggaatagctc ctggaaacgg gtggtaatac cggatgctcc gctccatcgc atggtggggt 180
gggaaatgct tttgcggcat gggatggggt cgcgtcctat cagcttgttg gcggggtgat 240
ggcccaccaa ggcgttgacg ggtagccggc ctgagagggt gaccggccac attgggactg 300
agatacggcc cagactccta cgggaggcag cagtggggaa tattgcacaa tgggcgcaag 360
cctgatgcag cgacgccgcg tgcgggatgg aggccttcgg gttgtaaacc gcttttgttc 420
aagggcaagg cacggtttcg gccgtgttga gtggattgtt cgaataagca ccggctaact 480
acgtgccagc agccgcggta atacgtaggg tgcgagcgtt atccggattt attgggcgta 540
aagggctcgt aggcggttcg tcgcgtccgg tgtgaaagtc catcgcctaa cggtggatct 600
gcgccgggta cgggcgggct ggagtgcggt aggggagact ggaattcccg gtgtaacggt 660
ggaatgtgta gatatcggga agaacaccaa tggcgaaggc aggtctctgg gccgtcactg 720
acgctgagga gcgaaagcgt ggggagcgaa caggattaga taccctggta gtccacgccg 780
taaacggtgg atgctggatg tggggccctt tccacgggtc ccgtgtcgga gccaacgcgt 840
taagcatccc gcctggggag tacggccgca aggctaaaac tcaaagaaat tgacgggggc 900
ccgcacaagc ggcggagcat gcggattaat tcgatgcaac gcgaagaacc ttacctgggc 960
ttgacatgtg ccggatcgcc gtggagacac ggtttccctt cggggccggt tcacaggtgg 1020
tgcatggtcg tcgtcagctc gtgtcgtgag atgttgggtt aagtcccgca acgagcgcaa 1080
ccctcgccgc atgttgccag cgggtgatgc cgggaactca tgtgggaccg ccggggtcaa 1140
ctcggaggaa ggtggggatg acgtcagatc atcatgcccc ttacgtccag ggcttcacgc 1200
atgctacaat ggccggtaca acgcggtgcg acacggtgac gtggggcgga tcgctgaaaa 1260
ccggtctcag ttcggatcgc agtctgcaac tcgactgcgt gaaggcggag tcgctagtaa 1320
tcgcggatca gcaacgccgc ggtgaatgcg ttcccgggcc ttgtacacgc cgcccgtcaa 1380
gtcatgaaag tgggtagcac ccgaagccgg tggcccgacc cttgtggggg gagccgtcta 1440
aggtgaga 1448
<210> 3
<211> 571
<212> DNA
<213>saccharomyces bayanus bacterium
<400> 3
atgcttagta cggcgagtga gcggcaaaag ctcaaatttg aaatctggta ccttcggtgc 60
ccgagttgta atttggagag ggcaactttg gggccgttcc ttgtctatgt tccttggaac 120
aggacgtcat agagggtgag aatcccgtgt ggcgaggagt gcggttcttt gtaaagtgcc 180
ttcgaagagt cgagttgttt gggaatgcag ctctaagtgg gtggtaaatt ccatctaaag 240
ctaaatattg gcgagagacc gatagcgaac aagtacagtg atggaaagat gaaaagaact 300
ttgaaaagag agtgaaaaag tacgtgaaat tgttgaaagg gaagggcatt tgatcagaca 360
tggtgttttg tgccctctgc tccttgtggg taggggaatc tcgcatttca ctgggccagc 420
atcagttttg gtggcaggat aaatccatag gaatgtagct tgcctcggta agtattatag 480
cctgtgggaa tactgccagc tgggactgag gactgcgacg taagtcaagg atgctggcat 540
aatggttata tgccgcccgt cttgaaacac g 571
<210> 4
<211> 1412
<212> DNA
<213>streptococcus fecalis
<400> 4
gaacgctggc ggcgtgccta atacatgcaa gtagaacgct gaagagagga gcttgctctt 60
cttggatgag ttgcgaacgg gtgagtaacg cgtaggtaac ctgccttgta gcgggggata 120
actattggaa acgatagcta ataccgcata acaatggatg acacatgtca tttatttgaa 180
aggggcaatt gctccactac aagatggacc tgcgttgtat tagctagtag gtgaggtaat 240
ggctcaccta ggcgacgata catagccgac ctgagagggt gatcggccac actgggactg 300
agacacggcc cagactccta cgggaggcag cagtagggaa tcttcggcaa tgggggcaac 360
cctgaccgag caacgccgcg tgagtgaaga aggttttcgg atcgtaaagc tctgttgtaa 420
gtcaagaacg ggtgtgagag tggaaagttc acactgtgac ggtagcttac cagaaaggga 480
cggctaacta cgtgccagca gccgcggtaa tacgtaggtc ccgagcgttg tccggattta 540
ttgggcgtaa agcgagcgca ggcggtttga taagtctgaa gttaaaggct gtggctcaac 600
catagttcgc tttggaaact gtcaaacttg agtgcagaag gggagagtgg aattccatgt 660
gtagcggtga aatgcgtaga tatatggagg aacaccggtg gcgaaagcgg ctctctggtc 720
tgtaactgac gctgaggctc gaaagcgtgg ggagcgaaca ggattagata ccctggtagt 780
ccacgccgta aacgatgagt gctaggtgtt ggatcctttc cgggattcag tgccgcagct 840
aacgcattaa gcactccgcc tggggagtac gaccgcaagg ttgaaactca aaggaattga 900
cgggggcccg cacaagcggt ggagcatgtg gtttaattcg aagcaacgcg aagaacctta 960
ccaggtcttg acatcccgat gctatttcta gagatagaaa gttacttcgg tacatcggtg 1020
acaggtggtg catggttgtc gtcagctcgt gtcgtgagat gttgggttaa gtcccgcaac 1080
gagcgcaacc cctattgtta gttgccatca ttcagttggg cactctagcg agactgccgg 1140
taataaaccg gaggaaggtg gggatgacgt caaatcatca tgccccttat gacctgggct 1200
acacacgtgc tacaatggtt ggtacaacga gttgcgagtc ggtgacggcg agctaatctc 1260
ttaaagccaa tctcagttcg gattgtaggc tgcaactcgc ctacatgaag tcggaatcgc 1320
tagtaatcgc ggatcagcac gccgcggtga atacgttccc gggccttgta cacaccgccc 1380
gtcacaccac gagagtttgt aacacccgaa gt 1412
Claims (10)
1. a kind of complex microbial inoculum, which is characterized in that including Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and excrement hammer
Bacterium.
2. complex microbial inoculum according to claim 1, which is characterized in that the deposit number of the Lactobacillus brevis is
CGMCC NO.16125;The deposit number of the bifidobacterium longum is CGMCC NO.16126;The preservation of the saccharomyces bayanus bacterium is compiled
Number be CGMCC NO.16127;The deposit number of the streptococcus fecalis is CGMCC NO.16128.
3. complex microbial inoculum according to claim 2, which is characterized in that the 16SrDNA sequence of the Lactobacillus brevis
With the sequential structure as shown in SEQ ID NO.1;The 16SrDNA sequence of the bifidobacterium longum has such as SEQ ID NO.2
Shown in sequential structure;The 26S rDNA sequence of the saccharomyces bayanus bacterium has the sequential structure as shown in SEQ ID NO.3;It is described
The 16SrDNA sequence of streptococcus fecalis has the sequential structure as shown in SEQ ID NO.4.
4. complex microbial inoculum described in any one of claim 1-3 is preparing recuperating gastrointestinal tract health and/or is improving
The health care product of immunity, dairy products, the application in drug.
5. application according to claim 4, which is characterized in that the complex microbial inoculum preparation treatment and/or
Application in the health care product of pre- anti-diarrhea, drug.
6. a kind of preparation method of complex microbial inoculum, which comprises the steps of: take in claim 1-3 and appoint
Lactobacillus brevis, bifidobacterium longum, saccharomyces bayanus bacterium and streptococcus fecalis described in meaning one are made as freeze-dried powder respectively, remix uniformly i.e.
?.
7. the preparation method of complex microbial inoculum according to claim 6, which is characterized in that specifically include following step
It is rapid:
Protective agent is added into the Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis respectively,
It is uniformly mixed, pre-freeze 1-3h at a temperature of placing it in -30~-50 DEG C, distil 10- at a temperature of being subsequently placed in -10~-20 DEG C
20h, then the 10-20h that distils at a temperature of being placed in -10~-25 DEG C, then in 20-30 DEG C of at a temperature of secondary distillation 1-5h, in vacuum
It is lower place 1-5h after to get the freeze-dried powder of the Lactobacillus brevis, the freeze-dried powder of the bifidobacterium longum, the saccharomyces bayanus bacterium jelly
Dry powder and the freeze-dried powder of the streptococcus fecalis, by four kinds of freeze-dried powders be uniformly mixed to get.
8. the preparation method of complex microbial inoculum according to claim 7, which is characterized in that the protective agent is degreasing
One of milk powder, maltose, sucrose, soluble starch, mannitol, sodium glutamate, L-cysteine, gelatin are a variety of.
9. the preparation method of complex microbial inoculum according to claim 8, which is characterized in that specifically include following step
It is rapid:
(1) Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis are taken, respectively fermented and cultured,
Obtain the fermentation liquid of the Lactobacillus brevis, the fermentation liquid of the bifidobacterium longum, the fermentation liquid of the saccharomyces bayanus bacterium, the excrement chain
The fermentation liquid of coccus;
(2) four kinds of fermentation liquids that fermentation obtains in step (1) are taken, placing it in revolving speed respectively is under 8000-12000r/min, from
Heart 10-30min collects bacterium mud, obtains four kinds of bacterium muds;
(3) protective agent, the weight ratio of the protective agent and the bacterium mud are separately added into bacterium mud obtained in step (2)
For 3:1, it is uniformly mixed, pre-freeze 3h at a temperature of placing it in -40 DEG C, distil 15h at a temperature of being subsequently placed in -15 DEG C, then sets
Distil 2h at a temperature of 25 DEG C, after placing 2h under vacuum, makes the water content of the bacterium mud less than 5%, obtains the short cream
The freeze-dried powder of bacillus, the freeze-dried powder of the bifidobacterium longum, the freeze-dried powder of the saccharomyces bayanus bacterium and the freeze-drying of the streptococcus fecalis
Powder, by four kinds of freeze-dried powders be uniformly mixed to get.
10. the preparation method of complex microbial inoculum according to claim 9, which is characterized in that described in step (1)
Lactobacillus brevis, the bifidobacterium longum, the saccharomyces bayanus bacterium and the streptococcus fecalis obtain fermentation liquid by three grade fermemtation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910030845.8A CN109652334A (en) | 2019-01-11 | 2019-01-11 | A kind of complex microbial inoculum and its preparation method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910030845.8A CN109652334A (en) | 2019-01-11 | 2019-01-11 | A kind of complex microbial inoculum and its preparation method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109652334A true CN109652334A (en) | 2019-04-19 |
Family
ID=66120009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910030845.8A Pending CN109652334A (en) | 2019-01-11 | 2019-01-11 | A kind of complex microbial inoculum and its preparation method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109652334A (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109517765A (en) * | 2019-01-11 | 2019-03-26 | 谭瑛 | A kind of streptococcus fecalis and its application |
CN110628683A (en) * | 2019-10-22 | 2019-12-31 | 江苏恒丰强生物技术有限公司 | Probiotic compound live bacterium preparation for preventing and treating chicken diarrhea and preparation method thereof |
CN112094735A (en) * | 2020-09-02 | 2020-12-18 | 山东省食品药品检验研究院 | Simulated digestion system device and method for detecting microorganisms in medicine |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
CN101328469A (en) * | 2008-07-09 | 2008-12-24 | 扬州大学 | Streptococcus thermophilus grx02 having alcoholic liver damage protection function, preparation and use thereof |
CN101671638A (en) * | 2009-09-28 | 2010-03-17 | 中国农业大学 | New strain of bifidobacterium and fermentative preparation method and application thereof |
CN102614225A (en) * | 2011-01-28 | 2012-08-01 | 湖北国力生物技术开发有限公司 | Composite active probiotic preparation and its industrial production method |
CN103764154A (en) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
CN107964520A (en) * | 2017-12-28 | 2018-04-27 | 内蒙古和美科盛生物技术有限公司 | A kind of compound lactobacillus probiotics and preparation method and application |
CN108473944A (en) * | 2015-09-15 | 2018-08-31 | 庆熙大学校产学协力团 | Novel lactobacillus casei and application thereof with various functions |
CN108641991A (en) * | 2018-07-11 | 2018-10-12 | 江苏恒丰强生物技术有限公司 | A kind of composite viable bacteria preparation and preparation method and its application |
-
2019
- 2019-01-11 CN CN201910030845.8A patent/CN109652334A/en active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1273838A (en) * | 2000-04-26 | 2000-11-22 | 济南三株药业有限公司 | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics |
CN101328469A (en) * | 2008-07-09 | 2008-12-24 | 扬州大学 | Streptococcus thermophilus grx02 having alcoholic liver damage protection function, preparation and use thereof |
CN101671638A (en) * | 2009-09-28 | 2010-03-17 | 中国农业大学 | New strain of bifidobacterium and fermentative preparation method and application thereof |
CN102614225A (en) * | 2011-01-28 | 2012-08-01 | 湖北国力生物技术开发有限公司 | Composite active probiotic preparation and its industrial production method |
CN103764154A (en) * | 2011-06-10 | 2014-04-30 | 普洛特拉有限公司 | Pharmaceutical compositions containing pediococcus and methods for reducing the symptoms of gastroenterological syndromes |
CN108473944A (en) * | 2015-09-15 | 2018-08-31 | 庆熙大学校产学协力团 | Novel lactobacillus casei and application thereof with various functions |
CN107964520A (en) * | 2017-12-28 | 2018-04-27 | 内蒙古和美科盛生物技术有限公司 | A kind of compound lactobacillus probiotics and preparation method and application |
CN108641991A (en) * | 2018-07-11 | 2018-10-12 | 江苏恒丰强生物技术有限公司 | A kind of composite viable bacteria preparation and preparation method and its application |
Non-Patent Citations (2)
Title |
---|
张卓丹等: "二株嗜热链球菌益生特性的体外研究", 《中国乳品工业》 * |
程秀芳等: "两株益生菌的抑菌性及其合生元对试验小鼠肠道菌群作用研究", 《齐鲁药事》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109517765A (en) * | 2019-01-11 | 2019-03-26 | 谭瑛 | A kind of streptococcus fecalis and its application |
CN110628683A (en) * | 2019-10-22 | 2019-12-31 | 江苏恒丰强生物技术有限公司 | Probiotic compound live bacterium preparation for preventing and treating chicken diarrhea and preparation method thereof |
CN112094735A (en) * | 2020-09-02 | 2020-12-18 | 山东省食品药品检验研究院 | Simulated digestion system device and method for detecting microorganisms in medicine |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100378214C (en) | Probiotic bacterium: lactobacillus fermentum | |
CN106282072B (en) | Compound lactobacillus microecological preparation and preparation method and application thereof | |
CN109504637B (en) | Pediococcus pentosaceus and application thereof | |
CN102277325B (en) | Enterococcus faecalis strain for feed purpose and use thereof | |
KR20010031131A (en) | Competitive exclusion culture for swine | |
CN113249255B (en) | Bacillus subtilis for preventing and controlling enteritis of poultry and application thereof | |
WO2008023580A1 (en) | Animal feed additive | |
CN110878266B (en) | Lactobacillus johnsonii and application thereof | |
CN1273838A (en) | Nutritive composition containing symbiotic fermentation culture medium of dead probiotics | |
CN109652334A (en) | A kind of complex microbial inoculum and its preparation method and application | |
CN112029674A (en) | Bacillus coagulans BC01 for improving intestinal microecology and relieving constipation and application thereof | |
CN1057563C (en) | Bacterial stain of bacillus subtilis and application thereof | |
CN109486732B (en) | Bifidobacterium longum and application thereof | |
CN114107134B (en) | Brevibacillus laterosporus and application thereof | |
KR101230813B1 (en) | Probiotics Agent Against Saprolegnia sp. | |
KR102130646B1 (en) | Novel lactobacillus salivarius and feed additives for aquacultural fish and crustacea comprising the same | |
Herich et al. | The effect of Lactobacillus paracasei and Raftilose P95 upon the non-specific immune response of piglets | |
CN109576165B (en) | Saccharomyces bayanus and application thereof | |
CN111743158A (en) | Probiotic tablet with function of enhancing immunity and preparation method thereof | |
CN107586746B (en) | Lactic acid bacteria with effect of preventing and treating cow mastitis and application thereof | |
CN1059235C (en) | Preparation of living bacillus subtilis and preparation method thereof | |
CN116200305A (en) | Enterococcus durans strain with anti-inflammatory property, culture method and application | |
CN109517765A (en) | A kind of streptococcus fecalis and its application | |
CN114085789A (en) | Pediococcus pentosaceus MA.WTPQJ01 and application thereof | |
CN109536424A (en) | A kind of Lactobacillus brevis and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190419 |
|
WD01 | Invention patent application deemed withdrawn after publication |